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OBJECTIVES: Estimate current healthcare costs for HCV and its consequences in a
large, US managed care organization (MCO). METHODS: Patients with ICD-9 diag-
nosis codes for Hepatitis C viral (HCV) infection (1st diagnosisindex date), age 18
years with 6 months of continuous enrollment were identified in a large, MCO
claims database from 1/1/2002 to 3/31/2010. HCV patients were matched 1:10 to
patients without an HCV diagnosis or advanced liver disease (ALD), based on gen-
der, age, index year (where synthetic index dateenrollment  median post-en-
rollment days to case index date), hospital referral region (HRR) state, pre-index
healthcare costs, alcoholism, HIV/AIDS, andmodified Charlson Comorbidity Index.
Cases were stratified by disease state: chronic HCV without liver involvement (C-
HCV), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular
carcinoma (HCC), or liver transplant. Mean per-member per-year (PMPY) costs
were estimated post-index (total post-index cost of all patients /[sum of all post-
index days/365]). Incremental PMPY costs for HCV patients vs. matched controls
were estimated overall and by each disease state. RESULTS: 34,597 HCV patients
were matched to 330,435 controls. Mean age of cases was 49.9 (8.5) years; 62%
were female; 78% had C-HCV, 4% CC, 12% DC, 3% HCC, and 3% transplant. Incre-
mental costs vs. controls overall were $9,681 PMPY. Incremental PMPY costs for
patients with ALD were DC: $27,845, HCC: $43,671, and transplant: $93,609. For
patients without ALD, incremental PMPYs were C-HCV: $5,870, and CC: $5,330.
Incremental drug costs forHCV treatmentwere $2,739 overall, ranging from$1,893-
$8,736 for different states. C-HCV and CC drug costs were $2,659 and $3,102,
respectively. CONCLUSIONS: Current estimates of HCV cost burden to MCOs were
higher than previously reported and increased substantially with progression to
ALD. The higher estimated costs of managing chronic HCV were likely due to high
non-liver related costs among HCV patients or imprecise coding of CC.
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OBJECTIVES: HIV-infected patients are at an increased risk of cardiovascular dis-
eases (CVD), resulting in the need for integration of CVD screening into HIV treat-
ment guidelines. We evaluated different CVD screening strategies in HIV-infected
patients with regard to effectiveness, costs, and cost-effectiveness. METHODS:
Cost-effectiveness analysis using a microsimulation model reflecting coronary ar-
tery disease (CAD), myocardial dysfunction, and heart failure in HIV-positive men.
Data sources: Patient-level data from HIV-HEART study, literature, German reim-
bursement data. Time horizon: Diagnostic phase, lifetime. Perspective: Societal.
Interventions: No screening (SOC), ECGBNPwith echocardiographystress-ECG if
pathologic ECG or BNP (“Outpatient”), ECGBNPechocardiographystress-ECG
(“Cardiologist”), “Cardiologist” with coronary computed tomography angiography
if pathologic echocardiography or stress-ECG (“Cardiologist ”). Outcomes: Diag-
nostic results, discounted quality-adjusted life expectancy (QALE) and lifetime
costs, incremental cost-effectiveness ratio (ICER). RESULTS: The initial CAD prev-
alence in HIV-infected men aged 40 years was estimated at 5.9%. One-time “Out-
patient”, “Cardiologist”, and “Cardiologist ” screenings correctly diagnosed 7, 43,
and 48 out of 59 CAD patients per 1,000 patients at €46/person, €109/person, and
€429/person, respectively. The expected QALE was estimated at 16.54, 16.56, 16.71,
and 16.75 years for SOC, and one-time “Outpatient”, “Cardiologist”, and “Cardiolo-
gist” screenings atmean lifetime costs per patient of €321,348, €322,279, €327,670,
and €328,864, respectively. “Outpatient” and “Cardiologist” were extendedly dom-
inated by “Cardiologist ”. The ICER of “Cardiologist ” vs. SOC was €35,791 per
quality-adjusted life year (QALY). When screening frequency was varied between
one and five years at one-year intervals, “Cardiologist” was extendedly dominated
by “Cardiologist”. The predicted ICERs for the non-dominated strategies as com-
pared to SOC were €34,508, €40,489, and €49,373 per QALY for annual “Outpatient”
and “Cardiologist ” at 5- and 4-year intervals, respectively. CONCLUSIONS: Our
preliminary analyses suggest that integrating routine CVD screening into HIV
treatment guidelines could be clinically beneficial and cost-effective.
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OBJECTIVES: Adalimumab and etanercept are patient self-administered biologic
agents used in rheumatoid arthritis (RA). Prescription refill gap analyses may be
conducted to understand patient refill behavior as a proxy for compliance. The
objective of this study was to evaluate gaps between prescription refills of adali-
mumab or etanercept across multiple databases and compare results of different
methodologies. METHODS: Data were obtained from three retrospective claims
databases (HealthCore Integrated Research Database-HIRD [adalimumab or etan-
ercept initiation 07/2004-10/2008], MarketScan Commercial and Medicare Supple-
mental Claims databases [01/2003-06/2008], and Wolters Kluwer Pharma Solu-
tions-WKPS database [01/2004-12/2008]). Inclusion criteria: 18 years old, 2 RA
diagnosis codes (ICD-9 code 714.xx), no biologic therapy 6 or 12 months prior to
current therapy, one year of treatment persistence (HIRD and MarketScan only),
and no selected inflammatory conditions. Mean gaps (days) in refills were calcu-
lated among all RA patients in MarketScan and WKPS, and calculated among only
those patients with 1 day of gap in HIRD. Analyses included the first 15 refill
periods. RESULTS: Data from 15,818 adalimumab and 25,175 etanercept patients
were analyzed. Mean adalimumab gaps spanned 1.3 to 8.4 and 6.8 to 11.4 days in
MarketScan and WKPS, respectively. Mean adalimumab gaps spanned 17.2 to 33.4
days in HIRD when calculated among only those patients with 1 day of gap in
refilling. Mean etanercept gaps spanned 1.3 to 10.9, 6.6 to 14.2, and 16.3 to 37.4 days
forMarketScan,WKPS, andHIRD, respectively.CONCLUSIONS:Results acrossmul-
tiple databases substantiate that refill gaps exist among adalimumab and etaner-
cept users during each refill period. The specific methodology for calculating refill
gaps should be considered. The extent of delayed refills may be underestimated
when calculated across an entire population, instead of only among those with
evidence of a gap. Further research is needed examining clinical and economic
consequences associated with therapy gaps.
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OBJECTIVES: Medication adherence has been linked to better health outcomes.
Therefore, a comprehensive understanding of the predictors of adherence is es-
sential for formulating adherence-improving strategies. Existingmethods have not
considered evaluation of heterogeneous impacts of predictors at different parts
(quantiles) of the adherence distribution as defined bymedication possession ratio.
Using the novel econometric framework of unconditional quantile regression
(UQR), this study assesses the heterogeneity of impacts of adherence predictors for
anAlzheimer’s disease (AD) population.METHODS:This retrospective claims anal-
ysis identified AD patients from a large US health plan that initiated oral AD ther-
apy (rivastigmine, donepezil, galantamine, or memantine) between 1/1/2006 and
12/31/2007. Baseline characteristics were assessed during the 6-month pre-index
period; medication adherence was assessed during the 1-year post-index period.
UQR was estimated at 10th, 20th, . . ., 90th quantiles. Predictors of adherence iden-
tified from the data included age, gender, indicator of mental health insurance
coverage, region, commercial vs. Medicare insurance, log cost, comorbidity, and
formulary tier for the AD medication. RESULTS: Baseline medication count was
positively associated with adherence (p0.05) in the upper half of the adherence
distribution. Having mental health coverage is negatively associated with adher-
ence in all but the 10th and 20th quantiles but the impact was substantially higher
in the first half of the adherence distribution. Baseline (log) cost was positively
associated with adherence in the 40th and upper quantiles of the adherence distri-
bution. For patients in the 80th and 90th quantiles, the number of baseline office
visits predicted lower adherence. Compared to patients from the East, patients
from the South were less likely to be adherent in the 60th and 70th quantiles.
CONCLUSIONS:The study results highlight the heterogeneity of impacts of various
adherence predictors – a predictor may be statistically significant only in specific
quantiles of the adherence distribution, and the impacts may vary substantially
between quantiles.
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OBJECTIVES: To investigate the impact of multiple medication compliance on the
occurrence of cardiovascular disease (CVD) outcomes using instrumental variables
(IV) to control for endogeneity bias. METHODS: We identified individuals who
newly start oral diabetes or hypertension medication therapy between July 2006
and June 2007 with the pre-existing comorbid hypertension or diabetes prescrip-
tion history during 6months of pre-index period using administrative claims from
amanaged care organization in southern California (N1565). Multiplemedication
compliance was defined as a proportion of days covered for both diabetes and
hypertension medications during three years of follow-up. Cardiovascular out-
comes included myocardial infarction, stroke, and peripheral vascular disease.
Instrumental variables estimation using physician related variables including a
dummy for the same prescribers for bothmedications, the percentage of follow-up
visit per physician, and the percentage of statin prescription per physician was
implemented. Parameter estimates were compared using probit and IV-probit
models.RESULTS:Mean complianceswere 0.636 (0.008) for diabetesmedications,
0.686 (0.008) for hypertension medications, and 0.527 (0.008) for both medica-
tions. After adjusting for age, gender, baseline clinical measures (Hemoglobin A1C,
blood pressure, and lipid), pre-existing condition (either diabetes or hypertension),
and Elixhauser-comorbidity, adherence to both medications was not significantly
associated with decreased CVD rate (0.0700.118, p0.554) based on probit
model. After controlling for endogeneity, however, the impact of multiple
medication adherence became statistically significant using IV-probit model
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